Oral presentations
|
Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials
Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey T.R., Mulenga WNV, Mwamabazi M, Szubert A, White E, Walker A.S., Elyanu P.J., Kekitiinwa A.R., Bamford A, Rojo P, Crichton S, Gibb D, Turkova A, Musiime V, Ford D. on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams. Oral Presentation: at 17th International Workshop on Pediatrics & HIV 2025; 2025 July 11-12; Kigali, Rwanda. |
|
Growth trajectories before and after switching to dolutegravir in children living with HIV in the ODYSSEY trial
Chan M.K., Crichton S, Mujuru H.A., Kekitiinwa A.R., Lugemwa A, Kityo C.M., Ahimbisibwe G.M., Variava E, Violari A, Cotton M, Archary M, Cressey T.R., Puthanakit T, Bandi S, Bwakura-Dangarembizi M, Bbuye D, Atwine L, Kaudha E, White E, Giaquinto C, Rojo P, Gibb D.M., Turkova A, Ford D. and the ODYSSEY Trial Team. Oral Presentation: at 17th International Workshop on Pediatrics & HIV 2025; 2025 July 11-12; Kigali, Rwanda. |
|
Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B
Jourdain G, Ngo-Giang-Huong N, Tierney C, Salvadori N, Pinilla M, Chanthalangsy T, Sengsilivanh S, Choumlivong K, Achalapong J, Liampongsabuddhi P, Sukrakanchana P, Tanasri S, Pol S, Keoluangkhot V, Jiamsiri S. Oral Presentation: at the Conference on Retroviruses and Opportunistic Infections (CROI); 2025 March 9-12; San Francisco, CA, USA. |
|
Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study
Bekker A, Salvadori S, Rabie H, du Toit S, Than-in-at K, Groenewald M, Capparelli E, Owen A, Cressey R, Lallemant M, Cotton M, Cressey T. Oral Presentation: at the Conference on Retroviruses and Opportunistic Infections (CROI); 2025 March 9-12; San Francisco, CA, USA. |
|
Pharmacokinetic modeling to support WHOweight band dosing of the new pediatric Darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children
Abdalla S, Lallemant M, Compagnucci A, Nardone A, Giaquinto C, Gibb D, Chabala C, Burger D, Hirt D, Cressey T.R., UNIVERSAL-2 Study Team. Oral Presentation: at the 13th IAS Conference on HIV Science (IAS 2025); 2025 July 13-17; Kigali, Rwanda. |
|
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
Wyncoll J, Archary M, Kamolrattana R, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Puthanakit T, Königs C, Behuhuma O, Welch S, Saïdi Y, Marques L, Ahimbisibwe GM, Holden L, Giaquinto C, Rojo P, Gibb DM, Turkova A, White E, Ford D. and the ODYSSEY Trial Team. Oral Presentation: at 17th International Workshop on Pediatrics & HIV 2025; 2025 July 11-12; Kigali, Rwanda. Oral Presentation: at the 13th IAS Conference on HIV Science (IAS 2025); 2025 July 13-17; Kigali, Rwanda. |
|
Prevention from mother-child transmission
Jourdain G. Invited oral presentation. International HBV Cure ANRS MIE Workshop, 12th edition, Paris, 11 June 2025. |
|
Long-acting Cabotegravir (CAB) plus Rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 Week 48 Outcomes
Gaur AH, Baltrusaitis K, Capparelli EV, Moye JH, Yin DE, Violari A, Heckman B, Buisson S, Van Solingen-Ristea RM, Harrington CM, Marzinke MA, Lowenthal ED, Ward S, Milligan R, Best BM, Townley E, Agwu AL, McCoig C, Huang J, Roberts G, Cheung A, Crauwels H, Eygen VV, Krotje C, Zabih S, Masheto G, Ounchanum P, Aurpibul L, Korutaro V, Moore CB. Oral abstract presentation at the 25th International AIDS Conference (AIDS 2024); 2024 July 22-26; Munich, Germany. |
|
ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART
Mujuru HA, White EM, Kekitiinwa AR, Lugemwa A, Kityo CM, Musoke P, Cressey TR, Variava E, Violari A, Archary M, Cotton MF, Puthanakit T, Rojo P, Turkova A. Oral Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Tenofovir-diphosphate concentrations and viral suppression following monthly point-of-care urine tenofovir testing among adults initiating antiretroviral therapy: Primary outcome of the randomised controlled STREAM HIV trial
N. Garrett, K.K Thomas, J. Dorward, Y. Sookrajh , E. Hill, A. Bardon, M. Khanyile, U. Singh, P. Munatsi, N. Samsunder, M. Wang, P. BelaunzaranZamudio, N. Naicker, D. Donnell, C. Celum, M. Gandhi, P. Moodley, T.R Cressey, P.K Drain. Oral abstract presentation at the 25th International AIDS Conference (AIDS 2024); 2024 July 22-26; Munich, Germany. |
|
From adolescence to adulthood: 12 years of follow-up of a cohort of adolescents born with HIV in Thailand.
Le Cœur S, Ngoc Minh PH, Sriphetcharawut S, Jongpaijitsakul P, and the TEEWA study group. Oral presentation at: the "Journée Scientifique Sidaction 2023", in Paris on 31 March 2023. |
|
ABACAVIR DOSING IN NEONATES FROM BIRTH: A PHARMACOKINETIC ANALYSIS
A. Bekker, E. Capparelli, A. Violari, M F. Cotton, R. Mathiba, A A. Wiznia, R. Browning, J. Moye, B. Graham, E. Decloedt, H. Rabie, M. Mirochnick, TR. Cressey. Spotlight Abstract: 605 at Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6-10; Virtual. |
|
ADEQUATE DACLATASVIR EXPOSURES IN CHILDREN 14-35 KG WITH AVAILABLE ADULT FORMULATIONS
TR. Cressey, M. Abbassi, M. Lallemant, G. Indolfi, M. Al-Nahari, S. Farid, P. Easterbrook, M. Penazzato, M. H. El-Sayed. Spotlight Abstract: 444 at Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6-10; Virtual. |
|
High HCV cure rates in C-FREE, first community-based study offering testing and treatment of viral hepatitis and HIV among people who use drugs and their partners in Thailand
T. Wansom, A. Thongmee, S. Chittmittrapap, T. Saraporn, S. Hasuwannakit, S. Waeuseng, K. Wanavanakorn, N. Chotirosniramit, B. Intharabut, R. Teuansiri, K. Kulprayong, A. Waesateh, T. Chumwangwapee, S. Pattarasuteewong, S. Pattarasuteewong, T. Pinyosinwat, C. Wongsuwon, V. Ngammee, S. Phueakchai, S. Lawpoolsri, S. Mills, P. Creac'H, G. Jourdain, A. Avihingsanon, N. Phanuphak, N. Durier. Oral Abstract: OAB0103 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
IMPLICATION OF MEASURING URINE TENOFOVIR BY RAPID LATERAL FLOW ASSAY FOR DOSE RECENCY
X. Niu, D. Sevenler, S. Dossantos, R. Sandlin, M. Toner, TR. Cressey, PK. Drain. Spotlight Abstract: 353 at Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6-10; Virtual. |
|
URINE TENOFOVIR CONCENTRATIONS ARE LOWER AMONG INDIVIDUALS TAKING TAF THAN TDF
K.A. Johnson, M. Spinelli, X. Niu, D. Glidden, S. MaWhinney, M. Morrow, H. Okochi, TR. Cressey, PK. Drain, M. Gandhi, P. Anderson. Spotlight Abstract: 355 at Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6-10; Virtual. |
|
VALIDATION OF RAPID SEMIQUANTITATIVE LATERAL FLOW ASSAY FOR URINE TENOFOVIR
D. Sevenler, S. Dossantos, X Niu, TR. Cressey, M. Toner, R. Sandlin, PK. Drain Spotlight Abstract: 352 at Conference on Retroviruses and Opportunistic Infections (CROI); 2021 March 6-10; Virtual. |
